221 related articles for article (PubMed ID: 16029424)
1. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model.
Ackermann J; Beermann F
Pigment Cell Res; 2005 Aug; 18(4):315-9. PubMed ID: 16029424
[TBL] [Abstract][Full Text] [Related]
2. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF.
Sarkar-Agrawal P; Vergilis I; Sharpless NE; DePinho RA; Rünger TM
J Natl Cancer Inst; 2004 Dec; 96(23):1790-3. PubMed ID: 15572761
[TBL] [Abstract][Full Text] [Related]
3. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.
Ackermann J; Frutschi M; Kaloulis K; McKee T; Trumpp A; Beermann F
Cancer Res; 2005 May; 65(10):4005-11. PubMed ID: 15899789
[TBL] [Abstract][Full Text] [Related]
4. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
Bai M; Yu NZ; Long F; Feng C; Wang XJ
Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
[TBL] [Abstract][Full Text] [Related]
5. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.
Yang J; Luan J; Yu Y; Li C; DePinho RA; Chin L; Richmond A
Cancer Res; 2001 Nov; 61(22):8150-7. PubMed ID: 11719444
[TBL] [Abstract][Full Text] [Related]
6. Advances in malignant melanoma: genetic insights from mouse and man.
Kabbarah O; Chin L
Front Biosci; 2006 Jan; 11():928-42. PubMed ID: 16146783
[TBL] [Abstract][Full Text] [Related]
7. Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRas(Q61K) ; Cdkn2a(-/-) transgenic mice.
Campagne C; Reyes-Gomez E; Battistella M; Bernex F; Château-Joubert S; Huet H; Beermann F; Aubin-Houzelstein G; Egidy G
Pigment Cell Melanoma Res; 2013 Sep; 26(5):735-42. PubMed ID: 23647911
[No Abstract] [Full Text] [Related]
8. Carcinogen treatment in mouse selectively expressing activated N-Ras Q61K in melanocytes recapitulates metastatic cutaneous melanoma development.
Contassot E; Jankovic D; Schuler P; Preynat-Seauve O; Gehrke S; Kerl K; Beermann F; French LE
Pigment Cell Melanoma Res; 2012 Mar; 25(2):275-8. PubMed ID: 22128787
[TBL] [Abstract][Full Text] [Related]
9. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
[TBL] [Abstract][Full Text] [Related]
10. [Alternative protein p19ARF: a genuine tumor suppressor gene].
Larsen CJ
Bull Cancer; 1998 Apr; 85(4):304-6. PubMed ID: 9752293
[TBL] [Abstract][Full Text] [Related]
11. Molecular regulation of melanocyte senescence.
Bennett DC; Medrano EE
Pigment Cell Res; 2002 Aug; 15(4):242-50. PubMed ID: 12100489
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice.
Tolleson WH; Doss JC; Latendresse J; Warbritton AR; Melchior WB; Chin L; Dubielzig RR; Albert DM
Arch Ophthalmol; 2005 Aug; 123(8):1088-94. PubMed ID: 16087843
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis.
Ferguson B; Konrad Muller H; Handoko HY; Khosrotehrani K; Beermann F; Hacker E; Soyer HP; Bosenberg M; Walker GJ
Pigment Cell Melanoma Res; 2010 Dec; 23(6):771-80. PubMed ID: 20718941
[TBL] [Abstract][Full Text] [Related]
14. Differential oncogenic potential of activated RAS isoforms in melanocytes.
Whitwam T; Vanbrocklin MW; Russo ME; Haak PT; Bilgili D; Resau JH; Koo HM; Holmen SL
Oncogene; 2007 Jul; 26(31):4563-70. PubMed ID: 17297468
[TBL] [Abstract][Full Text] [Related]
15. [Of mice and humans. Updates on susceptibility and tumor suppression of malignant melanoma].
Hautarzt; 2002 Jan; 53(1):88-9. PubMed ID: 11968172
[No Abstract] [Full Text] [Related]
16. Molecular pathogenesis of cutaneous melanocytic neoplasms.
Ibrahim N; Haluska FG
Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
[TBL] [Abstract][Full Text] [Related]
17. Met amplification and tumor progression in Cdkn2a-deficient melanocytes.
Vanbrocklin MW; Robinson JP; Whitwam T; Guilbeault AR; Koeman J; Swiatek PJ; Vande Woude GF; Khoury JD; Holmen SL
Pigment Cell Melanoma Res; 2009 Aug; 22(4):454-60. PubMed ID: 19422607
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
19. Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells.
Zhang H; Rosdahl I
Int J Oncol; 2004 Feb; 24(2):331-5. PubMed ID: 14719109
[TBL] [Abstract][Full Text] [Related]
20. MITF pathway mutations in melanoma.
Yokoyama S; Salma N; Fisher DE
Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
[No Abstract] [Full Text] [Related]
[Next] [New Search]
